Evidence map›Paper›PMID 41568362›Full record

ArticleFrontiers in oncology2025

Identification of the

Marta Brunetti, Kristin Andersen, Ingvild Lobmaier, Francesca Micci

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marta BrunettiSection for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Kristin AndersenSection for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Ingvild LobmaierDepartment of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Francesca MicciSection for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aim: Lipomas are benign tumors of adipocytic origin. The most frequent chromosome rearrangement in lipomas involves the high-mobility group AT-hook 2 gene ( Materials and Methods: The two lipomas were selected because their karyotype showed an 8;12-rearrangement with the very same breakpoint position. The cases were investigated using RNA sequencing, reverse transcription polymerase chain reaction (RT-PCR), Sanger sequencing techniques, Fluorescence Results: RNA sequencing and RT-PCR of the two lipomas showed the presence of the Conclusions: The

Indexed as

CIBAR1 divergent transcript (CIBAR1-DT)cytogeneticsfluorescence in situ hybridizationfusion genehigh mobility group AT-hook 2 (HMGA2) gene

Identifiers

PMID41568362
PMCPMC12815754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.